Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment

Fig. 4

Complete remission rates for patients in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial. a Primary endpoint outcomes among RAVE trial subjects stratified by the Granularity Index (GI). b Primary endpoint outcomes among RAVE trial subjects treated with either rituximab or cyclophosphamide in the absence of stratification. Fisher’s exact test was used to calculate significance between rates of complete remission on rituximab and cyclophosphamide. *10 of the 197 original trial subjects did not have flow cytometry data at baseline

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us